Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

Author:

Grimm Hans Peter1,Schumacher Vanessa1,Schäfer Martin2,Imhof-Jung Sabine2,Freskgård Per-Ola1,Brady Kevin1,Hofmann Carsten1,Rüger Petra2,Schlothauer Tilman2,Göpfert Ulrich2,Hartl Maximilian2,Rottach Sylvia2,Zwick Adrian2,Seger Shanon1,Neff Rachel1,Niewoehner Jens2,Janssen Niels1

Affiliation:

1. Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland

2. Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, Germany

Funder

F. Hoffmann-La Roche

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Reference49 articles.

1. Is beta-amyloid accumulation a cause or consequence of Alzheimer’s disease?;Wang S;J Alzheimers Parkinsonism Dement,2016

2. 2021 Alzheimer's disease facts and figures

3. US Food and Drug Administration (FDA). FDA’s decision to approve new treatment for Alzheimer’s disease [press release]; 2021 June 7 [accessed 2023 June 28]. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease.

4. US Food and Drug Administration (FDA). FDA grants accelerated approval for Alzheimer’s disease treatment [press release]; 2023 January 6 [accessed 2023 June 28]. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment.

5. Aging NNIo. NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial; 2023 [accessed 2023 March 16]. https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3